SMT201600087B - Metodo per l’identificazione della sensibilità di un paziente a una terapia di inibizione della telomerasi - Google Patents

Metodo per l’identificazione della sensibilità di un paziente a una terapia di inibizione della telomerasi

Info

Publication number
SMT201600087B
SMT201600087B SM201600087T SM201600087T SMT201600087B SM T201600087 B SMT201600087 B SM T201600087B SM 201600087 T SM201600087 T SM 201600087T SM 201600087 T SM201600087 T SM 201600087T SM T201600087 B SMT201600087 B SM T201600087B
Authority
SM
San Marino
Prior art keywords
telomerasi
sensitivity
patient
identification
inhibition therapy
Prior art date
Application number
SM201600087T
Other languages
English (en)
Inventor
Calvin B Harley
Laurence Elias
Jennifer Smith
Mark J Ratain
Fabio Benedetti
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of SMT201600087B publication Critical patent/SMT201600087B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
SM201600087T 2008-10-17 2016-03-24 Metodo per l’identificazione della sensibilità di un paziente a una terapia di inibizione della telomerasi SMT201600087B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10649108P 2008-10-17 2008-10-17
PCT/US2009/060526 WO2010045245A1 (en) 2008-10-17 2009-10-13 Method for identification of sensitivity of a patient to telomerase inhibition therapy

Publications (1)

Publication Number Publication Date
SMT201600087B true SMT201600087B (it) 2016-07-01

Family

ID=42106854

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20170535T SMT201700535T1 (it) 2008-10-17 2009-10-13 Metodo per l’identificazione della sensibilità di un paziente a una terapia di inibizione della telomerasi
SM201600087T SMT201600087B (it) 2008-10-17 2016-03-24 Metodo per l’identificazione della sensibilità di un paziente a una terapia di inibizione della telomerasi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20170535T SMT201700535T1 (it) 2008-10-17 2009-10-13 Metodo per l’identificazione della sensibilità di un paziente a una terapia di inibizione della telomerasi

Country Status (14)

Country Link
US (8) US8877723B2 (it)
EP (4) EP2342360B1 (it)
CY (2) CY1117234T1 (it)
DK (2) DK3029154T3 (it)
ES (4) ES2566338T3 (it)
HR (2) HRP20160067T1 (it)
HU (2) HUE027213T2 (it)
LT (1) LT3029154T (it)
NO (1) NO3029154T3 (it)
PL (2) PL2342360T3 (it)
PT (3) PT3719139T (it)
SI (2) SI3029154T1 (it)
SM (2) SMT201700535T1 (it)
WO (1) WO2010045245A1 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014085632A1 (en) * 2012-11-30 2014-06-05 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
KR20250151565A (ko) 2017-07-28 2025-10-21 제론 코포레이션 골수형성이상 증후군의 치료 방법
CN109662968B (zh) * 2017-10-13 2021-05-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
AU2019389005B2 (en) 2018-11-29 2024-06-20 Geron Corporation Methods of treating myelodysplastic syndrome
KR20230041707A (ko) * 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5776679A (en) 1994-07-07 1998-07-07 Geron Corporation Assays for the DNA component of human telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5741677A (en) 1995-06-07 1998-04-21 Geron Corporation Methods for measuring telomere length
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
ATE362546T1 (de) 1995-10-12 2007-06-15 Lansdorp Peter M Verfahren zum nachweis von mehrfachkopien einer wiederholungssequenz in einem nukleinsäuremolekül
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
JP2001507229A (ja) 1996-12-20 2001-06-05 ジェロン コーポレイション テロメラーゼのrna成分を検出および阻害するための方法
US6156763A (en) * 1998-02-04 2000-12-05 Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
US6995145B1 (en) 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
DK1210357T3 (da) 1999-09-10 2008-07-21 Geron Corp Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
PT1282443E (pt) 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US9777312B2 (en) * 2001-06-30 2017-10-03 Enzo Life Sciences, Inc. Dual polarity analysis of nucleic acids
CA2474468C (en) 2002-01-31 2014-03-25 University Of Utah Amplifying repetitive nucleic acid sequences
US20040234961A1 (en) 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
US9169516B2 (en) 2003-01-24 2015-10-27 University Of Utah Research Foundation Methods of predicting mortality risk by determining telomere length
KR101298493B1 (ko) 2003-09-09 2013-08-21 제론 코포레이션 텔로머라제 억제를 위한 변형 올리고뉴클레오티드
ME02933B (me) 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
DE102005024834B3 (de) 2005-05-31 2007-01-04 Lucas Automotive Gmbh Verfahren und System zur Steuerung einer Kraftfahrzeug-Feststellbremse während eines Halts
NZ565654A (en) * 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
BRPI0619476A2 (pt) 2005-12-05 2011-10-04 Wyeth Corp composições de interleucina-11 e métodos de uso
ES2407957T3 (es) * 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
US20100291560A1 (en) 2007-03-27 2010-11-18 The Johns Hopkins University Methods and compositions for diagnosis and treatment of dyskeratosis congenita and related disorders
WO2009073751A2 (en) 2007-12-04 2009-06-11 Geron Corporation Hair follicle pharmacodynamic assay for telomerase activity
US20090298709A1 (en) 2008-05-28 2009-12-03 Affymetrix, Inc. Assays for determining telomere length and repeated sequence copy number
US20110207128A1 (en) 2010-02-16 2011-08-25 Cawthon Richard M Methods and kits for determining biological age and longevity based on gene expression profiles
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
WO2014085632A1 (en) 2012-11-30 2014-06-05 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Also Published As

Publication number Publication date
PT3029154T (pt) 2017-12-06
HUE037447T2 (hu) 2018-08-28
HK1256479A1 (en) 2019-09-27
HRP20171536T1 (hr) 2018-01-26
US20230114322A1 (en) 2023-04-13
ES2645872T3 (es) 2017-12-11
EP3719139B1 (en) 2022-11-30
PT3719139T (pt) 2023-03-06
US9617583B2 (en) 2017-04-11
PL3029154T3 (pl) 2018-03-30
ES2789580T3 (es) 2020-10-26
EP3719139A1 (en) 2020-10-07
EP3330383B1 (en) 2020-02-12
US20150152488A1 (en) 2015-06-04
US20110263685A1 (en) 2011-10-27
EP2342360A1 (en) 2011-07-13
US20240318232A1 (en) 2024-09-26
LT3029154T (lt) 2017-12-27
HRP20160067T1 (hr) 2016-03-25
SMT201700535T1 (it) 2018-01-11
US8877723B2 (en) 2014-11-04
US20210269861A1 (en) 2021-09-02
PL2342360T3 (pl) 2016-06-30
NO3029154T3 (it) 2018-03-03
US20190382829A1 (en) 2019-12-19
EP3029154B1 (en) 2017-10-04
ES2939509T3 (es) 2023-04-24
SI3029154T1 (en) 2018-02-28
CY1117234T1 (el) 2017-04-05
EP2342360B1 (en) 2016-01-06
WO2010045245A1 (en) 2010-04-22
EP3029154A1 (en) 2016-06-08
HK1224341A1 (en) 2017-08-18
EP2342360A4 (en) 2012-10-03
SI2342360T1 (sl) 2016-04-29
US20220325327A1 (en) 2022-10-13
CY1119653T1 (el) 2018-04-04
US20170298421A1 (en) 2017-10-19
EP3330383A1 (en) 2018-06-06
DK2342360T3 (en) 2016-04-11
ES2566338T3 (es) 2016-04-12
US10196677B2 (en) 2019-02-05
HUE027213T2 (en) 2016-10-28
DK3029154T3 (en) 2017-12-11
PT3330383T (pt) 2020-05-06

Similar Documents

Publication Publication Date Title
SMT201600087B (it) Metodo per l’identificazione della sensibilità di un paziente a una terapia di inibizione della telomerasi
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
SMT201600475B (it) Procedimenti per la preparazione di inibitori di sglt2
DK2308885T3 (da) Nye forbindelser og fremgangsmåder for terapi
PL2506850T3 (pl) Sposoby podawania terapii pirfenidonem
PL3056224T3 (pl) Sposób sterylizacji
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
SMT201300007B (it) Trattamento di una malattia respiratoria
EP2485589A4 (en) HETEROARYL-BTK INHIBITORS
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
HUE038785T2 (hu) Hagyományos kínai gyógyszerkészítmény szív- és érrendszeri betegségek kezelésére
BRPI1006438A2 (pt) terapia adjuvante de cancer
PL2435825T3 (pl) Sposoby leczenia chorób
DE112010004110T8 (de) Neue parasitentherapie
EP2237793A4 (en) CATHEPSIN-B INHIBITORS
BRPI0917684A2 (pt) método terapêutico homeopático
IT1397349B1 (it) Metodo e kit per la produzione di un prodotto dentale
IT1398466B1 (it) Scala e metodo per la realizzazione di una scala
IT1400092B1 (it) Metodo di crioconservazione di polpa dentale
SMT201600403B (it) Composizioni per il trattamento della rosacea comprendenti chitosano e una ammide di un acido dicarbossilico
EP2417268A4 (en) DIAGNOSTIC PROCEDURE WITH PALB2
DK2396006T3 (da) Doramectinformulering med høj dosis
PT2406815T (pt) Método de posicionamento dos chips durante o fabrico de uma placa reconstituída
IT1394268B1 (it) Procedimento per la realizzazione di una calzatura
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina